Stemifai white logo

Transforming drug discovery and development for CNS diseases through precision medicine

From initial discovery to launch of a new therapy, our platform and scientific expertise will help make your next breakthrough the new standard of care.

  • Biobank of patient-derived neurons
  • Drug Response Profiles
  • Patient Stratification Strategies
  • Biomarkers & Companion Diagnostics
Get Started

Optimize drug discovery, development and commercialization

We collaborate with leading pharmaceutical organizations to bring evidence-based actionable insights to drug discovery, development and commercialization to improve success rates, reduce risks and costs, and unlock biological insights along the way.

Evidence-based prioritization

StemifAi leverages neuronal-based assays to provide actionable insights into MOA, drug effectiveness, and comparison between other candidate/commercial drugs

De-risk clinical trials and improve success rates

By querying StemifAi and associated data repository, a drug response profile is generated to guide patient enrichment and patient stratification strategies

Differentiated therapies

StemifAi empowered insights can be translated into complementary or companion diagnostics, or otherwise support market access activities through response characterization and a differentiated TPP

See All Use Cases
See All Use Cases

NeuroKaire Platform: StemifAI-Empowered

Supporting the full journey throughout the drug development life cycle

step 1
Target Discovery & Validation
  • Umbrella & Basket trials
  • Biomarker Strategy

Candidate Screening & Prioritization

Optimizing clinical trials

  • Differential expression between responders and non-responders
  • Genes with higher expression in responders enrich for neuronal ligand-receptor interactions
  • Gene module analysis shows a difference in a network involved in extracellular-matrix and collagen between responder and non-responders
Explore

‍
An arrow hitting a target with white background
A document having a microscope with white background

‍
step 2
Preclinical
  • Validated Human Model
  • Mechanistic Insight & Differentiation

Mechanistic Drug Differentiation

Enable gated decisions

  • Comparing between multiple drug candidates/ marketed drugs
  • Similarities and differences can be ascertained on specific patient populations
  • Powered by proprietary biomarkers, algorithms, and bio-repository
Explore
step 3
Phase I
  • Risk Mitigation
  • Optimize Design

Mechanistic Insight

Distinguishing responders & non-reponsder

  • Differential expression between responders and non-responders
  • Genes with higher expression in responders enrich for neuronal ligand-receptor interactions
  • Gene module analysis shows a difference in a network involved in extracellular-matrix and collagen between responder and non-responders
Explore

‍
A triangle having an exclamatory mark in center with white background
A microscope with white background

‍
step 4
Phase II/III
  • Biomarker Approach: Exploratory, Stratification, CDx
  • Regulatory Filing Data

Previous non-responders identified as responders to pipeline drugs

Non-responders to citalopram identified as responders to pipeline drug

  • Identify and target specific population that does not respond to current standard of care
  • Support pipeline drug or marketed drug move to first line for patient subset
Explore
step 5
Post-Marketing
  • Market Access
  • Repurposing
  • Differentiation

Moving To First Line With Response Biomarkers

The combination of genotype with gene expression levels provides a response biomarker for a marketed 3rd line drug.

  • A newly approved drug with limited commercial success
  • Biomarker approach identified a population of high responders
  • Market access in various regions is supported by the data
  • Targeted patient population for high response to support commercial strategy
Explore

‍
Three Giant bars with white background

Genetika+ Platform: StemifAi

Supporting the full journey throughout the drug development life cycle

An arrow hitting a target with white background
step 1

Target Discovery & Validation

  • Umbrella & Basket trials
  • Biomarker Strategy

Mechanistic Drug Differentiation

Enable gated decisions

  • Comparing between multiple drug candidates/ marketed drugs
  • Similarities and differences can be ascertained on specific patient populations
  • Powered by proprietary biomarkers, algorithms, and bio-repository
Explore
A document having a microscope with white background
step 2

Preclinical

  • Validated Human Model
  • Mechanistic Insight & Differentiation

Mechanistic Insight

Distinguishing responders & non-reponsder

  • Differential expression between responders and non-responders
  • Genes with higher expression in responders enrich for neuronal ligand-receptor interactions
  • Gene module analysis shows a difference in a network involved in extracellular-matrix and collagen between responder and non-responders
Explore
A triangle having an exclamatory mark in center with white background
step 3

Phase I

  • Risk Mitigation
  • Optimize Design

Candidate Screening & Prioritization

Optimizing clinical trials

  • Differential expression between responders and non-responders
  • Genes with higher expression in responders enrich for neuronal ligand-receptor interactions
  • Gene module analysis shows a difference in a network involved in extracellular-matrix and collagen between responder and non-responders
Explore
A microscope with white background
step 4

Phase II/III

  • Biomarker Approach: Exploratory, Stratification, CDx
  • Regulatory Filing Data

Previous non-responders identified as responders to pipeline drugs

Non-responders to citalopram identified as responders to pipeline drug

  • Identify and target specific popoulation that does not respond to current standard of care
  • Support pipeline drug or marketed drug move to first line for patient subset
Explore
Three Giant bars with white background
step 5

Post-Marketing

  • Market Access
  • Repurposing
  • Differentiation

Moving To First Line With Response Biomarkers

The combination of genotype with gene expression levels provides a response biomarker for a marketed 3rd line drug.

  • A newly approved drug with limited commercial success
  • Biomarker approach identified a population of high responders
  • Market access in various region is supported by the data
  • Targeted patient population for high response to support commercial strategy
Explore

Partnerships

Through our strategic partnerships with pharma and biotech companies we enable new treatments to come to market keeping precision medicine at the heart of drug development.

Share our vision for accelerating development and improving success rates.

Contact Us
Cheerful male person keeping a smile on his face while being satisfied with the result of the experiment.
A female doctor looking inside of microscope.
Stemifai coloured logo